Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.
Current Team (11)Update
Past Team (3)Update
Funding Rounds (3) - $65.4MUpdate
Board Members and Advisors (7)Update
Bill and Melinda Gates started the foundation because they believe every person should have the...
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early...
A Venture Capital Firm
Morningside Group is a private investment group founded in 1986 by the Chan family of Hong Kong.
MPH is a venture capital firm that invest in innovative research and development that focuses in...
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Emerging Technology VC
100 Acorn Park Drive
Cambridge, MA 02140
161 First St.
Cambridge, MA 02142
- 02/05/14 -nasdaq.com